Servicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO
Links relacionados
Similares en
SciELO
Compartir
Permalink
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
versión impresa ISSN 2225-5109versión On-line ISSN 2227-4731
Resumen
DIAZ-SILVA, Víctor Hugo; DOLORES TAFUR-HOYOS, Brenda Aurora; BURGA-GUEVARA, Diana Katherine y SANCHEZ NEIRA, Carlos. The deferral and relapse time after induction chemotherapy in children with acute lymphoblastic leukemia at a National Hospital in Lambayeque. Rev. Cuerpo Med. HNAAA [online]. 2022, vol.15, n.1, pp.81-85. Epub 31-Mar-2022. ISSN 2225-5109. http://dx.doi.org/10.35434/rcmhnaaa.2022.151.1097.
Objective:
To know the deferral and relapse time after induction chemotherapy in children with acute lymphoblastic leukemia (ALL) in a national hospital in Lambayeque
The study:
Analytical observational study of a retrospective cohort. The medical records of patients aged 2 and 15 years, with diagnosis of ALL, who achieved complete remission at the end of induction, treated in a national hospital in Lambayeque were reviewed.
Findings:
The patients studied had a median age of 5 years. Although the majority responded at the end of IA induction, still 43/75 children with ALL relapsed. Children with relapse had a deferral time of 6 days [IQR: 0-25] between the end of induction and the beginning of the consolidation phase.
Conclusion:
Deferral time ≥7 days in chemotherapy regimens affects the sustainability of remission.
Palabras clave : Leukemia acute lymphoblastic; Recurrence; Chemotherapy.
